Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis

Table 1 Main characteristics of all the studies included in the meta-analysis

Study	Study region	n	Mean age	Gender (M/F)	Clinical stage	Study design	Tumor type	Marker detection	Clinicopathological features	HR	Outcome	Quality assessment
Li et al[26], 2014	China	283	55.0 (18.0–79.0)	174/109	I-IV	Prospective	MF/PI/IG	HBsAg	NR	R	OS	8
Luo et al[27], 2014	China	1333	54.1 ± 10.9	912/421	I-IV	Retrospective	MF	HBsAg/anti-HCV	NR	R	OS	9
Uenishi et al[28], 2014	Japan	90	NR	61/29	I-IV	Retrospective	MF	HBsAg/anti-HCV	G	R	OS	9
Zhang et al[29], 2014	China	127	55.5 ± 11.8	102/25	I-IV	Retrospective	MF/PI/IG	HBsAg/anti-HCV	NR	R	OS/DFS	9
Liu et al[30], 2013	China	81	59.0 (30.0-76.0)	48/33	NR	Retrospective	MF/PI/IG	HBsAg/HBcAb	NR	R	OS	9
Wu et al[31], 2013	China	138	55	107/31	I-IV	Retrospective	MF/PI/IG	HBsAg/HBcAb	G, ALT, AST, TB, γ-GT, AFP, CA19-9, C, CF, D, TN, TS, LNM, VI	E	OS	8
Jiang et al[32], 2011	China	76	51.0 (40.0–60.0)	53/23	I-IV	Retrospective	MF/PI/IG	HBsAg	NR	R	OS	9
Peng et al[33], 2011	China	62	NR	NR	NR	Retrospective	MF/PI/IG	HBsAg/HBcAb	AFP, CA19-9, C, CF, D, TL, TN, TS, LNM, VI	NR	NR	8
Uenishi et al[34], 2011	Japan	35	61.0 (35.0-83.0)	11/24	II-IV	Retrospective	MF	HBsAg/anti-HCV	NR	E	OS	8
Zhou et al[11], 2011	China	155	55.0 ± 10.7 (27.0-76.0)	102/53	NR	Retrospective	MF/PI/IG	HBsAg	G, ALT, AST, TB, γ-GT, AFP, CA19-9, C, CF, D, TL, TN, TS, LNM, VI	R	OS/DFS	9
Zhang et al[12], 2010	China	40	56.0 (34.0-74.0)	24/16	I-IV	Retrospective	MF/PI/IG	HBsAg/HBcAb	NR	E	OS	8
Zhou et al[10], 2010	China	317	53.1 ± 10.5	223/94	NR	Retrospective	MF/PI/IG	HBsAg	G, ALT, AST, TB, γ-GT, AFP, CA19-9, C, CF, D, TL, TN, LNM, VI	NR	NR	8
Hai et al[13], 2005	Japan	38	NR	23/15	I-IV	Retrospective	MF/PI/IG	anti-HCV	G	E	OS	8
Asayama et al[35], 2002	Japan	67	62.0 (33.0-83.0)	36/31	NR	Retrospective	MF/PI/IG	HBsAg/anti-HCV	G	E	OS	8

n: Number of patients; M: Male; F: Female; HR: Hazard ration; R: Reported; NR: Not reported; E: Estimated; OS: Overall survival; DFS: Disease-free survival; MF: Mass-forming; PI: Periductal infiltrating; IG: Intraductal growth; G: Gender; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TB: Total bilirubin; γ-GT: γ-glutamyl transpeptidase; AFP: Alpha fetoprotein; CA19-9: Carbohydrate antigen 19-9; C: Cirrhosis; CF: Capsule formation; D: Differentiation; TL: Tumor location; TN: Tumor number; TS: Tumor size; LNM: Lymph node metastasis; VI: Vascular invasion.